Which has higher valuation and earnings, EXEL or IDYA?

Exelixis has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 5.82 $782.57M $3.18 17.12 IDEAYA Biosciences $218.71M 16.11 -$113.70M -$1.94 N/A

Is EXEL or IDYA more profitable?

Exelixis has a net margin of 35.33% compared to IDEAYA Biosciences' net margin of -75.93%. Exelixis' return on equity of 42.17% beat IDEAYA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% IDEAYA Biosciences -75.93% -16.73% -15.34%

Does the media prefer EXEL or IDYA?

In the previous week, Exelixis had 20 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 31 mentions for Exelixis and 11 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 1.37 beat Exelixis' score of 1.17 indicating that IDEAYA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 21 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IDYA or BMRN?

In the previous week, BioMarin Pharmaceutical had 7 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 18 mentions for BioMarin Pharmaceutical and 11 mentions for IDEAYA Biosciences. BioMarin Pharmaceutical's average media sentiment score of 1.59 beat IDEAYA Biosciences' score of 1.37 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 16 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor ARWR or IDYA?

In the previous week, Arrowhead Pharmaceuticals had 7 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 18 mentions for Arrowhead Pharmaceuticals and 11 mentions for IDEAYA Biosciences. Arrowhead Pharmaceuticals' average media sentiment score of 1.52 beat IDEAYA Biosciences' score of 1.37 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 15 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive IDEAYA Biosciences 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IDYA or MDGL?

In the previous week, Madrigal Pharmaceuticals had 3 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 14 mentions for Madrigal Pharmaceuticals and 11 mentions for IDEAYA Biosciences. Madrigal Pharmaceuticals' average media sentiment score of 1.59 beat IDEAYA Biosciences' score of 1.37 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 12 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer HALO or IDYA?

In the previous week, Halozyme Therapeutics had 14 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 25 mentions for Halozyme Therapeutics and 11 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 1.37 beat Halozyme Therapeutics' score of 1.32 indicating that IDEAYA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 20 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

IDEAYA Biosciences (IDYA) Competitors

$40.11 -1.66 (-3.97%)

As of 08/28/2026 04:00 PM Eastern

Compare

IDYA vs. EXEL, BMRN, ARWR, MDGL, and HALO

Should you buy IDEAYA Biosciences stock or one of its competitors? IDEAYA Biosciences's main competitors and comparable companies include Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Arrowhead Pharmaceuticals (ARWR), Madrigal Pharmaceuticals (MDGL), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does IDEAYA Biosciences compare to Exelixis?

Exelixis (NASDAQ:EXEL) and IDEAYA Biosciences (NASDAQ:IDYA) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Exelixis has a net margin of 35.33% compared to IDEAYA Biosciences' net margin of -75.93%. Exelixis' return on equity of 42.17% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%

Exelixis has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.1, meaning that its share price is 110% less volatile than the broader market.

85.3% of Exelixis shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 2.6% of Exelixis shares are held by insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Exelixis has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	5.82	$782.57M	$3.18	17.12
IDEAYA Biosciences	$218.71M	16.11	-$113.70M	-$1.94	N/A

In the previous week, Exelixis had 20 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 31 mentions for Exelixis and 11 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 1.37 beat Exelixis' score of 1.17 indicating that IDEAYA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	21 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEAYA Biosciences	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis presently has a consensus price target of $50.07, suggesting a potential downside of 8.05%. IDEAYA Biosciences has a consensus price target of $50.13, suggesting a potential upside of 24.97%. Given IDEAYA Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe IDEAYA Biosciences is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Summary

Exelixis beats IDEAYA Biosciences on 10 of the 17 factors compared between the two stocks.

How does IDEAYA Biosciences compare to BioMarin Pharmaceutical?

IDEAYA Biosciences (NASDAQ:IDYA) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

BioMarin Pharmaceutical has a net margin of 2.14% compared to IDEAYA Biosciences' net margin of -75.93%. BioMarin Pharmaceutical's return on equity of 5.32% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

IDEAYA Biosciences currently has a consensus target price of $50.13, suggesting a potential upside of 24.97%. BioMarin Pharmaceutical has a consensus target price of $88.79, suggesting a potential upside of 37.30%. Given BioMarin Pharmaceutical's higher possible upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.75

98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by company insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

IDEAYA Biosciences has a beta of -0.1, indicating that its share price is 110% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

In the previous week, BioMarin Pharmaceutical had 7 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 18 mentions for BioMarin Pharmaceutical and 11 mentions for IDEAYA Biosciences. BioMarin Pharmaceutical's average media sentiment score of 1.59 beat IDEAYA Biosciences' score of 1.37 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	16 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

BioMarin Pharmaceutical has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	16.11	-$113.70M	-$1.94	N/A
BioMarin Pharmaceutical	$3.22B	3.89	$348.90M	$0.37	174.78

Summary

BioMarin Pharmaceutical beats IDEAYA Biosciences on 14 of the 17 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and IDEAYA Biosciences (NASDAQ:IDYA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

In the previous week, Arrowhead Pharmaceuticals had 7 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 18 mentions for Arrowhead Pharmaceuticals and 11 mentions for IDEAYA Biosciences. Arrowhead Pharmaceuticals' average media sentiment score of 1.52 beat IDEAYA Biosciences' score of 1.37 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	15 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive
IDEAYA Biosciences	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arrowhead Pharmaceuticals has higher revenue and earnings than IDEAYA Biosciences. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.42	-$1.63M	-$2.25	N/A
IDEAYA Biosciences	$218.71M	16.11	-$113.70M	-$1.94	N/A

Arrowhead Pharmaceuticals presently has a consensus target price of $97.33, indicating a potential upside of 14.63%. IDEAYA Biosciences has a consensus target price of $50.13, indicating a potential upside of 24.97%. Given IDEAYA Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe IDEAYA Biosciences is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Arrowhead Pharmaceuticals has a net margin of -47.79% compared to IDEAYA Biosciences' net margin of -75.93%. IDEAYA Biosciences' return on equity of -16.73% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Arrowhead Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.1, indicating that its stock price is 110% less volatile than the broader market.

Summary

IDEAYA Biosciences beats Arrowhead Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Madrigal Pharmaceuticals?

IDEAYA Biosciences (NASDAQ:IDYA) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

IDEAYA Biosciences presently has a consensus price target of $50.13, indicating a potential upside of 24.97%. Madrigal Pharmaceuticals has a consensus price target of $699.64, indicating a potential upside of 31.08%. Given Madrigal Pharmaceuticals' higher probable upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

IDEAYA Biosciences has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	16.11	-$113.70M	-$1.94	N/A
Madrigal Pharmaceuticals	$1.28B	9.60	-$288.28M	-$12.89	N/A

In the previous week, Madrigal Pharmaceuticals had 3 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 14 mentions for Madrigal Pharmaceuticals and 11 mentions for IDEAYA Biosciences. Madrigal Pharmaceuticals' average media sentiment score of 1.59 beat IDEAYA Biosciences' score of 1.37 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	12 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Madrigal Pharmaceuticals has a net margin of -25.32% compared to IDEAYA Biosciences' net margin of -75.93%. IDEAYA Biosciences' return on equity of -16.73% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

IDEAYA Biosciences has a beta of -0.1, meaning that its stock price is 110% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.01, meaning that its stock price is 201% less volatile than the broader market.

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

IDEAYA Biosciences and Madrigal Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and IDEAYA Biosciences (NASDAQ:IDYA) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

Halozyme Therapeutics has a net margin of 24.86% compared to IDEAYA Biosciences' net margin of -75.93%. Halozyme Therapeutics' return on equity of 260.98% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%

Halozyme Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.1, meaning that its stock price is 110% less volatile than the broader market.

97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Halozyme Therapeutics had 14 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 25 mentions for Halozyme Therapeutics and 11 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 1.37 beat Halozyme Therapeutics' score of 1.32 indicating that IDEAYA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	20 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEAYA Biosciences	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Halozyme Therapeutics has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	8.56	$316.89M	$3.35	31.45
IDEAYA Biosciences	$218.71M	16.11	-$113.70M	-$1.94	N/A

Halozyme Therapeutics presently has a consensus target price of $91.20, suggesting a potential downside of 13.43%. IDEAYA Biosciences has a consensus target price of $50.13, suggesting a potential upside of 24.97%. Given IDEAYA Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe IDEAYA Biosciences is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Summary

Halozyme Therapeutics beats IDEAYA Biosciences on 9 of the 16 factors compared between the two stocks.

Get IDEAYA Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IDYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IDYA vs. The Competition

Export

Metric	IDEAYA Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.52B	$3.94B	$7.21B	$12.91B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-20.68	11.62	273.16	25.42
Price / Sales	16.11	1,349.86	626.01	91.27
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	2.94	16.53	12.98	6.14
Net Income	-$113.70M	-$22.80M	$3.48B	$348.86M
7 Day Performance	1.11%	-0.30%	0.13%	-0.80%
1 Month Performance	12.70%	11.84%	8.37%	5.56%
1 Year Performance	63.38%	55.46%	24.55%	15.57%

IDEAYA Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IDYA IDEAYA Biosciences	3.0977 of 5 stars	$40.11 -4.0%	$50.13 +25.0%	+63.4%	$3.52B	$218.71M	N/A	80	News Coverage Gap Up
EXEL Exelixis	3.2979 of 5 stars	$54.39 +2.4%	$50.07 -7.9%	+45.5%	$13.16B	$2.32B	17.10	1,077	Trending News Options Volume Analyst Revision
BMRN BioMarin Pharmaceutical	4.9099 of 5 stars	$69.33 +3.5%	$88.83 +28.1%	+11.0%	$12.97B	$3.22B	187.38	3,221	Positive News Analyst Forecast
ARWR Arrowhead Pharmaceuticals	2.5215 of 5 stars	$89.41 +1.7%	$97.33 +8.9%	+285.4%	$12.38B	$829.45M	N/A	400	Positive News
MDGL Madrigal Pharmaceuticals	3.5531 of 5 stars	$540.16 +3.0%	$689.93 +27.7%	+21.9%	$12.12B	$958.40M	N/A	90	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IDYA) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IDEAYA Biosciences (IDYA) Competitors

IDYA vs. EXEL, BMRN, ARWR, MDGL, and HALO

How does IDEAYA Biosciences compare to Exelixis?

Summary

How does IDEAYA Biosciences compare to BioMarin Pharmaceutical?

Summary

How does IDEAYA Biosciences compare to Arrowhead Pharmaceuticals?

Summary

How does IDEAYA Biosciences compare to Madrigal Pharmaceuticals?

Summary

How does IDEAYA Biosciences compare to Halozyme Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDYA vs. The Competition

IDEAYA Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IDEAYA Biosciences (IDYA) Competitors

IDYA vs. EXEL, BMRN, ARWR, MDGL, and HALO

How does IDEAYA Biosciences compare to Exelixis?

Is EXEL or IDYA more profitable?

Which has more risk and volatility, EXEL or IDYA?

Do institutionals & insiders have more ownership in EXEL or IDYA?

Which has higher valuation and earnings, EXEL or IDYA?

Does the media prefer EXEL or IDYA?

Do analysts rate EXEL or IDYA?

Summary

How does IDEAYA Biosciences compare to BioMarin Pharmaceutical?

Is IDYA or BMRN more profitable?

Do analysts recommend IDYA or BMRN?

Do institutionals & insiders have more ownership in IDYA or BMRN?

Which has more volatility & risk, IDYA or BMRN?

Does the media prefer IDYA or BMRN?

Which has preferable earnings and valuation, IDYA or BMRN?

Summary

How does IDEAYA Biosciences compare to Arrowhead Pharmaceuticals?

Does the media favor ARWR or IDYA?

Which has higher earnings and valuation, ARWR or IDYA?

Do analysts rate ARWR or IDYA?

Is ARWR or IDYA more profitable?

Do insiders & institutionals have more ownership in ARWR or IDYA?

Which has more volatility & risk, ARWR or IDYA?

Summary

How does IDEAYA Biosciences compare to Madrigal Pharmaceuticals?

Do analysts rate IDYA or MDGL?

Which has better earnings and valuation, IDYA or MDGL?

Does the media prefer IDYA or MDGL?

Is IDYA or MDGL more profitable?

Which has more volatility & risk, IDYA or MDGL?

Do institutionals and insiders hold more shares of IDYA or MDGL?

Summary

How does IDEAYA Biosciences compare to Halozyme Therapeutics?

Is HALO or IDYA more profitable?

Which has more risk & volatility, HALO or IDYA?

Do institutionals & insiders have more ownership in HALO or IDYA?

Does the media prefer HALO or IDYA?

Which has stronger valuation and earnings, HALO or IDYA?

Do analysts rate HALO or IDYA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDYA vs. The Competition

IDEAYA Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools